Distinct downstream targets of the medial prefrontal cortex underlie discrete antidepressant responses to ketamine
Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022 Ryota Shinohara, Brendan Hare, Rong-Jian Liu et al.
Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is the prototype for a potential new generation of glutamate-based antidepressants that rapidly relieve symptoms of depression within hours of treatment. Studies in rodents have demonstrated that neuroplasticity in the medial prefrontal cortex (mPFC) is critical for the antidepressant actions of ketamine. However, effector circuits...